Niga-ichigoside F1 |
| Catalog No.GC64215 |
Le niga-ichigoside F1, un triterpénoÏde ursane actif par voie orale, a des activités antihyperlipidémiantes et antioxydantes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 95262-48-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis[1].
Niga-ichigoside F1 (2.5, 5, 10, 20 μM; for 24 hours) inhibits lipid accumu-lation in free fatty acid (FFA)-treated HepG2 cells in a dose-dependent manner. Niga-ichigoside F1 has no effects on cell viability[1]. Both nuclear and cytoplasmic Nrf2 expressions are lowered in Con, Niga-ichigoside F1 (20 μM), FFA (1 mM), and Niga-ichigoside F1 plus FFA treated Nrf2-silenced cells[1].
Niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) alleviates hepatic steatosis, possibly by significantly interacting with high-fat diet (HFD) to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5) in four-week-old male C57BL/6J mice[1].
[1]. Shu-Fang Xia, et al. Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation. Food Funct. 2018 Feb 21;9(2):906-916.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *